Description

The mortality of leukemia ranks sixth among tumors while its incidence and mortality ranks first among malignant tumors for teenagers. The incidence of leukemia reaches two age peaks: 0-9 years old and above 60 years old.

Imatinib Mesylate was a tyrosine kinase inhibitor developed by Novartis. On May. 10, 2001, Imatinib Mesylate got FDA’s express approval with the trade name of Gleevec due to its groundbreaking anti-tumor mechanism. On Dec. 23, 2009, Imatinib Mesylate gained its status as the first-line treatment for chronic myelogenous leukemia under FDA’s approval. And now it has been approved for treatment of chronic myelogenous leukemia in more than 80 countries around the world.


View Full Report at: http://www.marketresearchreports.biz/analysis/289058


After entering Chinese market on Apr. 17, 2002, Imatinib Mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005-2014. Currently, Imatinib Mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Chia Tai Tianqing Pharmaceutical Group Co., Ltd and Hansoh Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014.

Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib Mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China’s economy develops, people’s income and purchasing power increases. Since an increasing number of patients are estimated to afford Imatinib Mesylate, its market size will expand further in China.


Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289058
Readers can get at least the following information through this report:

market size of Imatinib Mesylate in China
major manufacturers of Imatinib Mesylate in the Chinese market and their market share
retail price of Imatinib Mesylate in China
market outlook of Imatinib Mesylate in China

The author suggests the following groups of people purchase this report:

manufacturers of leukemia drugs
investors/ research institutions interested in Chinese medicine market
any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Content

1 Related Concepts of Imatinib Mesylate
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Imatinib Mesylate in China
2.1 Patent and Approval Status of Imatinib Mesylate in China
2.2 Major Manufacturers
2.3 Market Size
2.4 Smuggled Imatinib Mesylate in Chinese Market

3 Survey on Sales Status of Imatinib Mesylate in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions


Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]